[Form 4] Solid Biosciences Inc. Insider Trading Activity

Rhea-AI Filing Summary

Solid Biosciences Inc. (SLDB) reported an equity award to Chief Medical Officer Gabriel Brooks comprised of an employee stock option to purchase 142,500 shares at an exercise price of $6.17 and 71,250 restricted stock units (RSUs), both granted on 08/14/2025. The option expires on 08/14/2035 and both awards are held directly by the reporting person. The RSUs convert on a one-for-one basis to common stock. The awards vest over four years: 50% of the original shares vest on the second anniversary of the grant and 25% of the original shares vest each year thereafter until the fourth anniversary. The Form 4 was signed by an attorney-in-fact on 08/18/2025.

Insights

Corporate Governance Expert

TL;DR: Standard multi-year equity grant for an executive, designed for retention and alignment with shareholders.

The filing documents an equity compensation award to the Chief Medical Officer consisting of a 10-year option and time-based RSUs. The vesting schedule is back-loaded with half vesting at year two and the remainder over years three and four, indicating a medium-term retention structure. The direct ownership and one-for-one RSU conversion are clearly stated. There are no disclosures in this Form 4 about changes in cash compensation, acceleration clauses, or separate disposition of existing holdings.

Executive Compensation Analyst

TL;DR: Award sizes and terms are explicitly recorded; treatment is routine for executive-level grants.

The report shows a grant date of 08/14/2025 with an option exercise price of $6.17 for 142,500 shares and 71,250 RSUs, both exercisable/convertible under the stated vesting schedule and held directly. The 10-year option term aligns with common option practices. The filing contains no additional performance conditions or immediate exercises; it is a straightforward disclosure of new equity awards.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Brooks Gabriel

(Last) (First) (Middle)

C/O SOLID BIOSCIENCES INC.

500 RUTHERFORD AVENUE, THIRD FLOOR

(Street)

CHARLESTOWN MA 02129

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Solid Biosciences Inc. [ SLDB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/14/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$6.17	08/14/2025		A		142,500		(1)	08/14/2035	Common Stock	142,500	$0	142,500	D
Restricted Stock Units	(2)	08/14/2025		A		71,250		(1)	(1)	Common Stock	71,250	$0	71,250	D

Explanation of Responses:

1. The RSUs (as defined in footnote 2) together with this option were granted on August 14, 2025 (the "Grant Date") and vest over four years, with 50% of the original number of shares vesting on the second anniversary of the Grant Date and 25% of the original number of shares annually thereafter until the fourth such anniversary.

2. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock (the "RSUs").

	/s/ Kimberly Cornwell as attorney-in-fact for Gabriel Brooks	08/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.